Jyong Biotech Ltd. Ordinary Shares (NASDAQ:MENS) — Market Cap & Net Worth
Market Cap & Net Worth: Jyong Biotech Ltd. Ordinary Shares (MENS)
Jyong Biotech Ltd. Ordinary Shares (NASDAQ:MENS) has a market capitalization of $171.06 Million ($171.06 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17125 globally and #3857 in its home market, demonstrating a -0.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jyong Biotech Ltd. Ordinary Shares's stock price $2.25 by its total outstanding shares 76027696 (76.03 Million). Analyse cash efficiency ratio of Jyong Biotech Ltd. Ordinary Shares to see how efficiently the company converts income to cash.
Jyong Biotech Ltd. Ordinary Shares Market Cap History: 2025 to 2026
Jyong Biotech Ltd. Ordinary Shares's market capitalization history from 2025 to 2026. Data shows growth from $300.31 Million to $171.06 Million (0.00% CAGR).
Jyong Biotech Ltd. Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jyong Biotech Ltd. Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MENS by Market Capitalization
Companies near Jyong Biotech Ltd. Ordinary Shares in the global market cap rankings as of May 5, 2026.
Key companies related to Jyong Biotech Ltd. Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Jyong Biotech Ltd. Ordinary Shares Historical Marketcap From 2025 to 2026
Between 2025 and today, Jyong Biotech Ltd. Ordinary Shares's market cap moved from $300.31 Million to $ 171.06 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $171.06 Million | -43.04% |
| 2025 | $300.31 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Jyong Biotech Ltd. Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $171.06 Million USD |
| MoneyControl | $171.06 Million USD |
| MarketWatch | $171.06 Million USD |
| marketcap.company | $171.06 Million USD |
| Reuters | $171.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more